Vivacitas was formed in 2015, with the vision of our founders and Dr. Joseph Rubinfeld (co-founder of Amgen). Vivacitas is committed to creating new treatment options and improving the lives of cancer patients with solid tumors worldwide.

Cancer is the second leading cause of death in the United States. The global market for cancer therapeutics is growing rapidly, with revenues projected to reach $161 billion in 2026. (source: Allied Market Research 2021).

Currently, the standard of care for solid tumor cancers in the U.S is surgery and radiation/chemotherapy. Patients face significant challenges as treatment regimens must factor in the patient’s ability to tolerate the commonly used chemotoxins.

Significant numbers of cancer patients seek new treatment options especially in recurrent disease. According to the American Cancer Society, this is especially true in glioblastoma, colorectal, pancreatic, ovarian, and small cell lung cancers.